Harmony Biosciences Holdings, Inc. · NASDAQ:HRMY
Harmony Biosciences — Q4 2025 Earnings Presentation
18 slides from Harmony Biosciences's earnings presentation, Feb 24, 2026
Slide 1: Financial Results Q4 & FY 2025 & Business Update
Financial Results Q4 & FY 2025 & Business Update February 24, 2026 Copyright © 2026 Harmony Biosciences. All rights reserved.
Slide 2: Forward-Looking Statements
Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statement
Slide 3: 2026 Net Revenue Guidance
2026 Net Revenue Guidance $1.00B-$1.04B WAKIX Net Revenue Growth 2020–2025 $1,000 $1B+ 2026 NET REVENUE GUIDANCE $800 $869 Net Revenue ($M) $715 $600 $582 $400 $438 $200 $305 $160 $0 2020 2021 2022 2023 2024 2025 2026 Guidance On Track to Achieve $1B+ in Narcolepsy Alone 3 February 24, 2026 Harmony
Slide 4: WAKIX Is One of the Most Successful Orphan/Rare Launches
WAKIX® Is One of the Most Successful Orphan/Rare Launches Average Patients on WAKIX People Living With Narcolepsy in the U.S.1 9,000 400 8,000 500 Undiagnosed 400 100 Narcolepsy 7,000 250 300 350 150 250 Population 6,000 350 350 200 5,000 300 300 80,000 ~170,000 400 4,000 300 100 400 300 90,000 3,00
Slide 5: Strong Commercial Engine Driving Continued Growth
Strong Commercial Engine Driving Continued Growth Strong Foundation Recent Developments Implication DIFFERENTIATED Only non-scheduled treatment, 6+ years clinical experience Unique & Familiar PRODUCT unique MOA EXPERIENCED Many team members joined at launch Refined call plan, promo mix, messaging Tr
Slide 6: Pitolisant Franchise: Securing CNS Leadership by Addressing Unmet Patient Needs
Pitolisant Franchise: Securing CNS Leadership by Addressing Unmet Patient Needs EXTEND E X PA N D EXPLORE Pitolisant GR Pitolisant HD New Pitolisant Formulation • NDA Filing 2Q26 • Enhanced formulation with optimized • Mechanism-based approach supported by clinical data for pitolisant in fatigue • T
Slide 7: Pitolisant GR: Fast-To-Market Strategy to Extend WAKIX Franchise
Pitolisant GR: Fast-To-Market Strategy to Extend WAKIX® Franchise and Harmony’s Leadership in Narcolepsy POSITIVE PIVOTAL BIOEQUIVALENCE STUDY DOSING OPTIMIZATION STUDY COMPLETED 100% of the patients (46/46) able to initiate pitolisant GR Q1 2027 at the therapeutic dose,17.8mg, without titration; No
Slide 8: Pitolisant HD: Expand the Pitolisant Franchise with Enhanced Formulation
Pitolisant HD: Expand the Pitolisant Franchise with Enhanced Formulation and Differentiated Product Profile ENHANCED FORMULATION WITH OPTIMIZED PK PROFILE AND HIGHER DOSE Designed to address the need for greater efficacy in excessive daytime sleepiness (EDS) in patients with central disorders of hyp
Slide 9: Exploring Fatigue in Broader CNS Indications Based on Unique Histaminergic MoA
Exploring Fatigue in Broader CNS Indications Based on Unique Histaminergic MoA of Pitolisant CLINICAL EVIDENCE Physical, Cognitive, and Emotional Components of Fatigue Mediated WITH PITOLISANT through Histaminergic Circuits in the Brain Phase 2 PoC study in Myotonic Dystrophy Type 1 Promotes wakeful
Slide 10: Innovative Late-Stage Pipeline With Multiple Catalysts 2026–2028
Innovative Late-Stage Pipeline With Multiple Catalysts 2026–2028 PRODUCT INDICATION PRECLINICAL PHASE 1 PHASE 2 PHASE 3 REGULATORY FILING MARKETED PRODUCT EDS in Narcolepsy (Adult/Pediatric*) WAKIX® Cataplexy in Narcolepsy (Adult/Pediatric*) Pitolisant Gastro-Resistant (GR) in Narcolepsy Prader-Will
Slide 11: BP1.15205: Potential Best-In-Class Orexin 2 Receptor Agonist
BP1.15205: Potential Best-In-Class Orexin 2 Receptor (OX2R) Agonist PRECLINICAL DATA PRESENTATION AT SLEEP AND WSC Single-oral dose administration of BP1.15205 in transgenic mice produced significant and dose-dependent increases in total wakefulness time and sleep latency at every dose tested beginn
Slide 12: EPX-100: Safety and effectiveness data from ongoing OLE of Phase 3 Dravet Syndrome
EPX-100: Safety and effectiveness data from ongoing OLE of the Phase 3 Dravet Syndrome (DS) study presented at AES 2025 CLINICALLY MEANINGFUL REDUCTION IN SEIZURES Median reduction of ~50% in countable motor seizure frequency per 28 days (CMS-28) in participants who had at least 6-month exposure to
Slide 13: EPX-100: One of Most Advanced 5-HT2 Agonist Programs in DEEs
EPX-100: One of Most Advanced 5-HT2 (Serotonin) Agonist Programs in DEEs ESTABLISHED 5-HT2 (SEROTONIN) AGONIST MECHANISM OF ACTION MoA validated via the zebrafish model 1H 2027 ONGOING PHASE 3 TRIAL IN LENNOX-GASTAUT SYNDROME (LGS) (LIGHTHOUSE Study) Anticipate Topline Topline data anticipated 1H 20
Slide 14: Path to Long-Term Value Creation Beyond 2026
Path to Long-Term Value Creation Beyond 2026 2026 2027 2028 WAKIX Pitolisant GR PDUFA Pitolisant HD PDUFA Pediatric cataplexy approval Narcolepsy and IH Pitolisant HD Pitolisant PWS Phase 3 TLD in narcolepsy and EPX-100 PDUFA Phase 3 TLD idiopathic hypersomnia (IH) DS and LGS OX2R EPX-100 Pitolisant
Slide 15: Financial Highlights Q4 2025
Financial Highlights Q4 2025 CONSISTENT REVENUE Three Months Ended December 31, 2025 Twelve Months Ended December 31, 2025 22% GROWTH AND 21% $868.5 PROFITABILITY Net Product $714.7 Revenue $243.8 $201.3 ON TRACK TO Q4 2024 Q4 2025 FY 2024 FY 2025 BLOCKBUSTER Three Months Ended Twelve Months Ended S
Slide 16: Financial Summary Q4 2025
Financial Summary Q4 2025 Three Months Ended Twelve Months Ended December 31, December 31, Totals may not foot due to rounding 2025 2024 % Change 2025 2024 % Change Net Product Revenue $243.8 $201.3 21% $868.5 $714.7 22% Cost of Product Sold 68.5 54.4 26% 198.3 156.8 27% Total Operating Expenses $13
Slide 17: GAAP vs NON-GAAP Reconciliation Q4 2025
GAAP vs NON-GAAP Reconciliation Q4 2025 Three Months Ended Nine Months Ended December 31, December 31, Totals may not foot due to rounding 2025 2024 2025 2024 GAAP net income1 $22.5 $49.5 $158.7 $145.5 Non-cash interest expense2 0.2 0.2 0.6 0.7 Depreciation 1.5 0.0 1.5 0.3 Amortization3 6.0 6.0 23.8
Slide 18: company/harmonybiosciences/ @harmonybio harmony_biosciences
company/harmonybiosciences/ @harmonybio harmony_biosciences w w w. h a r m o n y b i o s c i e n c e s . c o m
Harmony Biosciences Holdings — Q4 2025 Earnings Presentation on 6ix